Industrial and Academic Neglected Disease Drug Discovery Collaborations - CDD Webinar

Slide deck for CDD's 2017 Q2 webinar featuring Julio Martin (GSK) and Michael Pollastri (Northeastern University)

Science

Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
•“Industrial and Academic Neglected Disease
Drug Discovery Collaborations”
•Town Hall Webinar
•June 28, 2017

Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Today’s Moderator
Industrial and Academic Neglected
Disease Drug Discovery Collaborations
Frank Cole, CDD
Head of Sales, Eastern US

Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Today’s Panelists
Industrial and Academic Neglected
Disease Drug Discovery Collaborations
Julio Martin PhD,
Head of Kinetoplastid Biology,
Director & GSK Fellow
GSK R&D, Tres Cantos,
Spain
Mike Pollastri, PhD
Associate Professor & Chair of
Chemistry & Chemical Biology
Northeastern University,
Boston, Massachusetts

Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Tres Cantos Medicines Development Campus
GSK R&D Site in Spain
4
Diseases of the Developing World (DDW)
DDW
150 scientists

Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
7
http://www.northeastern.edu/isec
www.northeastern.edu/pollastri
Twitter: @NUTrypKiller

Copyright © 2017 All Rights Reserved Collaborative Drug Discovery
Partnerships
at the helm
Industrial and Academic Neglected
Disease Drug Discovery Collaborations
IPK

The emergence of freely available PubChem and ChEMBL resources for chemical and biological Structure-Activity-Relationship (SAR) data has radically changed the global drug discovery informatics landscape. The heterogeneity of low throughput and high throughput chemical and biological data do nevertheless present some unique challenges – and opportunities – when creating large-scale community resources – for sophisticated purveyors of drug discovery data.

Antibiotic Discovery Webinar

Antibiotic Discovery Webinar – Getting Through the Discovery Wall

Therapeutically relevant bioassays

Human vs. Machine-Enhanced Scientific Discovery

This document summarizes a webinar titled "Human vs. Machine-Enhanced Scientific Discovery" hosted by Collaborative Drug Discovery, Inc. on September 21, 2016. It introduces the moderators and panelists which include experts from CDD, University of Miami, Stanford University, and biotech consultants. The webinar then discusses topics like semantic web, ontologies, controlled vocabularies, challenges of semantic annotation, and visions of future laboratory research. Resources like Protégé, BioPortal, CEDAR, BAO, LINCS, and DTO are also presented. Questions from attendees are addressed at the end.

Make better drug discovery decisions through collaborative analytics cdd we...

Tb Drug Accelerator Webinar

DayOne Experts - Next generation clinical trials

DayOne

Event introduction slides by Thomas Brenzikofer. Read the event report here:https://www.baselarea.swiss/baselarea-swiss/channels/innovation-report/2019/06/on-the-verge-of-being-born-next-generation-clinical-trials.html Tomasz Sablinski, Founder and CEO of Transparency Life Sciences raised the crunch question of the evening: Which industry is lagging behind the most in terms of digitization? Right, it is the healthcare industry! But who would have expected the usual lamentation of why this is the case; blaming regulatory constraints, scarce innovation culture, or unachievable technology barriers proved wrong. The appetite for change and finding new ways of doing things was too strong among Basel’s Healthcare innovators at the DayOne Expert Session on “Next Generation Digital Trials”. The idea of the event was to present a holistic view of the current standing in the digitizing clinical trials.

Domainex Ltd and Ark Therapeutics have extended their drug discovery agreement. Domainex will continue providing hit-finding and lead optimization services for Ark's therapeutic targets. The companies have worked together successfully for years, combining Domainex's drug design expertise with Ark's disease expertise. Dr. Trevor Perrior of Domainex commented that their collaboration has already achieved breakthroughs against challenging goals, and they look forward to further developing programs to deliver new disease treatments.

10th International Conference Compound Libraries 2014

Torben Haagh

VISIT THE CONFERENCE WEBSITE HERE: http://bit.ly/CompoundLibrariesSlideshare Maximizing information in early-phase R&D for an optimal library design and target selection We are excited to conduct the 10th annual meeting of the formerly known Compound Libraries conference! Over the last decade we have provided the pharmaceutical R&D community with a wonderful platform for exchanging knowledge and ideas about how best to optimize the qualification of drug candidates. We have hosted almost all major pharmaceutical companies and heard dozens of case-studies relating to important and acute issues. When returning back to the programs from previous years, it is interesting to look at the timeline of changing approaches, trends and market-related developments. Our topical spectrum ranged from compound management and acquisition to collaboration frameworks, open access, library design, screening and analysis. This year we bring you 15 case studies about the most burning issues in early-stage discovery today and offer you a valuable trend-analysis and networking with peers and colleagues from pharmaceutical companies, biotechs, CROs and academic research institutes. Don’t miss our 10th anniversary and join us in Berlin to take part at our legacy conference! Benefit from participating in discussions about the following topics: -10 years perspective on synthesizing and designing compound libraries -What is the role of ligand efficiency metrics in drug discovery? Have your say in this controversial debate! -Next generation library design - working towards better PPI and epigenetic libraries -Exploration of bioactive and novel chemical space by application of privileged structure concept design -Learn from Janssen’s experience with the assembly of the IMI European Lead Factory (ELF) library -What is the real potential of macrocycles and are they the drugs of the future?

How Effective Are The Supplements I'm Taking (request for participants)

HEMA Biosciences

The document summarizes a study comparing the effectiveness of over-the-counter omega-3 supplements to personalized omega-3 supplements from Hemavault. 20 participants were split into two groups, one taking OTC supplements and one taking Hemavault supplements, and had their omega-3 levels tested monthly over 12 weeks. Initial results found the Hemavault supplements led to higher omega-3 level increases for more participants, with one participant seeing a 36% increase. The document calls for more participants to help determine the relative effectiveness of different omega-3 supplement options and individuals' responses.

Agile Day Twin Cities - Lightning Talk (Repko)

Brian Repko

This document discusses product agility when developing treatments for diseases like cancer. It describes the complex and iterative process of drug discovery and development at Novartis, involving thousands of experiments, assays, and clinical trials across multiple sites. It emphasizes the need for continuous learning, visualizing complexity through various data sources, forming product teams of different experts, planning experiments to learn key scientific questions, and collaborating to clarify goals and explore new approaches. The overall process involves blending discovery work with clinical evaluation in an agile manner to efficiently gain knowledge and progress potential new treatments.

Using the CDD Vault for MM4TB

Sean Ekins

UC BRAID D4

CTSI at UCSF

The document discusses BRAID D4, a new initiative across the University of California system aimed at leveraging shared resources to enable drug and device discovery. The goals are to catalyze innovation that enhances development and testing of diagnostics and therapeutics. It notes challenges in translating research into clinical applications. D4 could help projects progress through the difficult period of late-stage preclinical development known as the "Valley of Death". The document outlines existing drug discovery resources at several UC campuses and a consensus to define D4's role in supporting the broader BRAID initiative through strategic planning.

Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2

Ajaz Hussain discusses the importance of excipient knowledge management, particularly regarding physical functionality and performance. He notes that many drug products now require precise control of complex material attributes supplied by excipients. Effective knowledge management is needed to understand and control excipient variability. Hussain also highlights current regulatory trends and the need to improve databases on inactive ingredients to better track excipient functionality.

Therapeutic Equivalence in Inequality and Our Quality Scorecard

I believe, and I know, that we can build and maintain effective pharmaceutical quality management systems (pQMS) when every pharmaceutical professional is empowered to contribute to improving the system they work in. A way I know to improve a pQMS from within is to illuminate paths to professional development for all to leverage “fractals” at every level and in every corner. This presentation describes my experiential learning to explain why I know so, how do I know what I know, and what you can do to verify or validate it at your level and in your corner.

Preliminary program of ISPOR Boston 2017

Bruno Vayssié

This document provides information about the upcoming ISPOR Boston conference on health economics and outcomes research (HEOR). Some key points: - The conference will be held from May 20-24, 2017 in Boston, MA and is expected to attract nearly 3,800 attendees from over 80 countries. - It will feature over 1,850 presentations on topics related to HEOR including modeling, economic evaluation, patient preferences, real-world evidence, and health policy decision making. - Plenary sessions will address pressing issues in US health policy, using social networks to impact population health, and the need for randomized controlled trials. - Pre-meeting short courses and educational symposia are also offered to enhance

RCSI Research Summer School - Dr Derick Mitchell - June 7th 2017

NIPTE, A Community of Knowledge at 2019 Research Conference

How to Build Effective Pharmaceutical Quality Managment System & Self-develop...

Building on the goals of your LIU education and training, we will learn how the Experience Economy has already changed and will continue to change, the healthcare and new drug pricing and development model and how it is impacting generic drugs. We will use the ICH Q10 model and adopt a system within a system framework to identify common effectiveness measures – Assurance, Availability, Adherence, and Affordability to understand how these may relate improvement of a system and development of individuals (Amgen case example). Finally, we will outline an easy to use/remember framework that we can use as a starting point in writing their a self- development plan.

UCD PharmTox event on Clinical Trials

Bill & Melinda Gates foundation - Ken Duncan

bluesquare

The document discusses partnerships in drug discovery for diseases that primarily impact developing countries. It focuses on the importance of partnerships like the TB Drug Accelerator (TBDA) in developing new treatments for tuberculosis. The TBDA is a partnership between pharmaceutical companies and research institutions that aims to develop a new one-month drug regimen for TB through open data sharing, collaborative research, and ensuring the best candidates advance. Such partnerships are a new paradigm that can help address bottlenecks in developing new TB drugs and serve as a model for other disease areas.

5 Ways Healthcare Brands Can Stand out to HCPs in the Digital Ecosystem

DRG Digital

Views for collaboration between pharmaceutical industry and academia a haapal...

Antti Haapalinna

The document discusses views on collaboration between the pharmaceutical industry and academia from Antti Haapalinna, Vice President of Research and Development at Orion Corporation. It notes that strategic partnerships can cover the entire R&D chain from early discovery to late-stage clinical development and marketing. Early-stage partnerships are often with smaller organizations that provide specific expertise to complement larger companies. Later-stage partnerships are usually with larger organizations for their clinical trial expertise and global reach. Key success factors include a mutual desire to develop new treatments, each party contributing unique capabilities, and professionally coordinated collaboration.

Mbec sponsor packet opportunities america21 - final

ScaleUp Partners LLC

Pistoia Alliance Debates: Text Mining for Pharma R&D in a Social World (17th ...

Pistoia Alliance

Text-mining of journal articles and other publications has long been a subject of interest. It already has applications across R&D and beyond into health care, for instance by analysing electronic health records. The technology has value but also has its limits. With new sources of text to mine becoming mainstream, such as Twitter feeds or Facebook posts that might reference a company’s brand or a drug’s efficacy or adverse events, existing technology needs to be adapted to keep pace. Not only that, but whole new compliance questions arise: does a fleeting mention on Twitter require the same response as a formal notification of an adverse event?

Genetic alliance

johndemello7

Insight-driven Medical Communications – Educating Neurologists

Medicalwriters.com

Presentation given by Wesley Portegies, CEO of Medicalwriters.com, at the 2018 Drug Information Association (DIA) annual meeting in Boston, MA. In order to develop effective Medical Education programs and materials, it is crucial to have a thorough understanding of the behavior, perceptions, and beliefs of your target audience. This presentation focuses on how you can use these insights to optimize your communications to Health Care Professionals (HCPs).

Changing the Medical Research Paradigm

RAWE_INC

Accelerating Clinical Trials trough Multi-Stakeholder Collaborations

WorldCongress

This conference offers delegates an in-depth view of the latest initiatives that are simplifying and improving the clinical trial experience for the patient through data-sharing and setting industry standards. Leading individuals from biopharma partnerships and consortia come together to share the results and impact of their projects, as well as insights on areas ripe for future collaboration. The conference provides delegates with opportunities to learn from one another in regard to what works now and a forum to discuss how to leverage and build on collective experiences to advance innovation across the wider community. We discuss: Responsible Clinical Trials Data Sharing – Protecting Intellectual Property While Enabling Public Access to Data. The Project Data Sphere Initiative – A New Data Sharing and Analytics Model for Cancer Research. Clinical Trials Transformation Initiative – Advancing Central IRBs, IND Safety and a Quality by Design Approach to Clinical Trial Operations. Lessons Learned from Pilot Studies on Risk-Based Monitoring Methodology to Identify Risk and Ensure Data Quality. A Model to Create, Share, and Re-Use Structured Content throughout the Clinical Trial Life Cycle – The Sanofi-TransCelerate Collaboration. CISCRP Recommendations – Communicate Trial Results to Participants to Improve Experience and Build Support for the Clinical Research Enterprise. http://www.worldcongress.com/events/PB14014/

What's hot

Domainex Ark Press Release June 2009 Final

dikheidi

10th International Conference Compound Libraries 2014

Torben Haagh

How Effective Are The Supplements I'm Taking (request for participants)

HEMA Biosciences

Agile Day Twin Cities - Lightning Talk (Repko)

Brian Repko

Using the CDD Vault for MM4TB

Sean Ekins

UC BRAID D4

CTSI at UCSF

What's hot (6)

Domainex Ark Press Release June 2009 Final

10th International Conference Compound Libraries 2014

How Effective Are The Supplements I'm Taking (request for participants)

Agile Day Twin Cities - Lightning Talk (Repko)

Using the CDD Vault for MM4TB

UC BRAID D4

Similar to Industrial and Academic Neglected Disease Drug Discovery Collaborations - CDD Webinar

Excipient Knowledge Management Mumbai 12 March 2015 Part 1 & 2

Therapeutic Equivalence in Inequality and Our Quality Scorecard

Preliminary program of ISPOR Boston 2017

Bruno Vayssié

RCSI Research Summer School - Dr Derick Mitchell - June 7th 2017

NIPTE, A Community of Knowledge at 2019 Research Conference

How to Build Effective Pharmaceutical Quality Managment System & Self-develop...

UCD PharmTox event on Clinical Trials

Bill & Melinda Gates foundation - Ken Duncan

bluesquare

5 Ways Healthcare Brands Can Stand out to HCPs in the Digital Ecosystem

DRG Digital

Views for collaboration between pharmaceutical industry and academia a haapal...

Antti Haapalinna

Mbec sponsor packet opportunities america21 - final

ScaleUp Partners LLC

Pistoia Alliance Debates: Text Mining for Pharma R&D in a Social World (17th ...

Pistoia Alliance

Genetic alliance

johndemello7

Insight-driven Medical Communications – Educating Neurologists

Medicalwriters.com

Changing the Medical Research Paradigm

RAWE_INC

Accelerating Clinical Trials trough Multi-Stakeholder Collaborations

WorldCongress

DIA Global Forum: Are Clinical Trials Ready to Embrace the IoE?

Jackie Brusch

The Internet of Everything (IoE) is having a major impact across many industries by connecting people, processes and data on a single network. The IoE brings opportunities to make clinical trials more efficient, cost-effective and less intrusive by enabling devices, sensors and applications to connect to healthcare systems via the internet. This allows for remote patient monitoring and the collection of real-time objective data from devices and wearables. The constant flow of rich data allows investigators to remotely manage patients' health, which has potential to speed up drug development times. However, clinical trials have yet to fully embrace the IoE and changes may be needed to regulations and processes to realize the IoE's benefits for research.

Presentation for umass workshop final 2

nanalaw

The document discusses how True Open Innovation and Boston Strategics' global network can improve drug development efficiency and lower costs. It outlines challenges in the pharmaceutical industry like decreased productivity and increased costs. It then describes how Boston Strategics uses a virtualized model and worldwide expert network to assemble project teams that can progress drug candidates through development faster and at lower expense than traditional models. Examples are provided of projects demonstrating savings of time and money. The goal is to establish an open innovation platform to facilitate drug development collaborations globally.

Irish Brain Council